GlassScriptPhysician profile
Robert C Czarnecki
NPI 1366432981
$6,282.86
in general payments reported to CMS, 2019-2025
21 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $635 · 2021: $759 · 2022: $987 · 2023: $1,174 · 2024: $1,102 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.78 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,629.93 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $762.80 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $705.00 | 2019-2025 | Dupixent |
| Genzyme Corporation | $652.89 | 2019-2025 | |
| Genentech USA, INC. | $380.89 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.84 | 2019-2023 | Spiriva Respimat |
| Csl Behring | $363.20 | 2019-2025 | Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $323.71 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $290.30 | 2019-2022 | |
| Amgen INC. | $197.41 | 2022-2025 | Tezspire |
| Kaleo, INC. | $108.32 | 2019-2023 | Auvi-Q |
| Alk-Abello, INC | $92.94 | 2019-2023 | Ragwitek, Grastek, Odactra |
| Optinose US, INC. | $77.44 | 2020-2022 | |
| Abbvie INC. | $74.40 | 2022-2023 | Ubrelvy |
| Covis Pharma Gmbh | $64.82 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $53.54 | 2025 | Neffy |
| Tersera Therapeutics LLC | $38.11 | 2023 | Quzyttir |
| Hikma Pharmaceuticals USA | $30.67 | 2024 | Ryaltris |
| Biocryst US Sales Co., LLC | $26.59 | 2021 | |
| Phadia US INC. | $19.04 | 2021 | |
| Merck Sharp & Dohme LLC | $16.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Czarnecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.